Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Early-stage Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Testing effectiveness (Phase 2)Looking for participantsNCT01042379
What this trial is testing

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerBreast Tumors+8 more
QuantumLeap Healthcare Collaborative 5,000
Large-scale testing (Phase 3)Active Not RecruitingNCT03725059
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Who this might be right for
Breast Cancer
Merck Sharp & Dohme LLC 1,240
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Not applicableLooking for participantsNCT06035016
What this trial is testing

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast Cancer
Peking Union Medical College Hospital 300
Large-scale testing (Phase 3)Active Not RecruitingNCT06747338
What this trial is testing

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Who this might be right for
Early or Locally Advanced HER2-positive Breast Cancer
Shanghai JMT-Bio Inc. 520
Testing effectiveness (Phase 2)WithdrawnNCT04273555
What this trial is testing

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Who this might be right for
HER2-positive Breast Cancer
University of Alabama at Birmingham
Large-scale testing (Phase 3)Study completedNCT04024462
What this trial is testing

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Hoffmann-La Roche 200
Testing effectiveness (Phase 2)Study completedNCT01565200
What this trial is testing

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Who this might be right for
HER-2 Positive Breast Cancer
Jules Bordet Institute 90
Testing effectiveness (Phase 2)Ended earlyNCT04249622
What this trial is testing

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+18 more
Mayo Clinic 20
Large-scale testing (Phase 3)Active Not RecruitingNCT02625441
What this trial is testing

Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Helsinki University Central Hospital 516
Testing effectiveness (Phase 2)Looking for participantsNCT06500208
What this trial is testing

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 48
Large-scale testing (Phase 3)Looking for participantsNCT05883852
What this trial is testing

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Who this might be right for
HER2 Positive Early Breast Cancer
Fudan University 1,406
Testing effectiveness (Phase 2)Looking for participantsNCT05035836
What this trial is testing

Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Who this might be right for
Breast CancerHER2-positive
M.D. Anderson Cancer Center 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04514419
What this trial is testing

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Who this might be right for
Breast Cancer
BioRay Pharmaceutical Co., Ltd. 408
Testing effectiveness (Phase 2)Study completedNCT00148681
What this trial is testing

Preoperative Herceptin and Navelbine for Breast Cancer

Who this might be right for
Breast CancerStage II Breast CancerStage III Breast Cancer
Dana-Farber Cancer Institute 49
Not applicableLooking for participantsNCT07084558
What this trial is testing

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Who this might be right for
Early and Locally Advanced Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 350
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Testing effectiveness (Phase 2)Looking for participantsNCT05020860
What this trial is testing

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmBreast Cancer Female+8 more
Baylor Breast Care Center 185
Large-scale testing (Phase 3)Study completedNCT00309556
What this trial is testing

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Who this might be right for
Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 536
Next Page